Efficacy Of Entresto In The Treatment Of Patients With Chronic Heart Failure And Its Effect On SST2

Objective To observe the improvement of clinical symptoms of patients with chronic heart failure(CHF)treated with Sandostatin(entresto)and its effect on soluble serum matrix lysin-2(The effects of ST2,end diastolic diameter of left ventricle,left ventricular ejection fraction and NT proBNP on ventricular remodeling and myocardial fibrosis in patients with chronic heart failure were evaluated.method From September 2017 to March 2019,60 patients with chronic heart failure and ejection fraction < 40% were randomly divided into the experimental group and the control group.They were treated with routine diuresis,cardiotonic therapy,vasodilation and other basic heart failure treatment.The experimental group was treated with sakubatravalin(gradually increased to 200 mg,twice a day),and the control group was treated with enalapril According to the blood pressure situation of patients,the blood pressure tolerance maximum dose was gradually increased from low dose to one or two times a day.Before treatment,1 month and 6 months after treatment,the levels of serum ST2,end diastolic diameter of left ventricle,left ventricular ejection fraction of heart,NT proBNP and other indexes were monitored.Results After one month of treatment,the levels of ST2,NT proBNP and LVEDd decreased and LVEF increased in the two groups,which was more significant in the experimental group(70.51±13.35?681.04±226.42?54.68±3.27?41.43±2.83 VS 80.71±16.82?828.41±206.31?56.68±3.19?39.65±2.57,P<0.05)?After6 months of treatment,ST2,NT proBNP,lved decreased and LVEF increased in the two groups,which was more significant in the experimental group(55.27±10.17?105.25±29.82?48.21±1.97?51.18±2.40 VS 64.64±21.26?137.45±51.19?49.52±1.57?49.07±2.45,P<0.05)?There was significant difference between the two groups in clinical effect and rehospitalization rate(P < 0.05)?Conclusion Six months after treatment of heart failure,the clinical effect of sakubatversartan is better than that of enalapril group,and the values of ST2,left ventricular end diastolic diameter,brain natriuretic peptide precursor are significantly lower than before,and left ventricular ejection fraction is significantly higher than before.Therefore,sakubatversartan can improve myocardial fibrosis and ventricular remodeling in patients with chronic heart failure.